Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Work In Process (2022 - 2025)

Jin Medical International (ZJYL) has disclosed Work In Process for 4 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • Quarterly Work In Process rose 9.45% to $1.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Sep 2025, up 9.45% year-over-year, with the annual reading at $1.9 million for FY2025, 9.45% up from the prior year.
  • Work In Process hit $1.9 million in Q3 2025 for Jin Medical International, up from $1.7 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $1.9 million in Q3 2025 to a low of $1.4 million in Q3 2022.
  • Historically, Work In Process has averaged $1.7 million across 4 years, with a median of $1.7 million in 2023.
  • Biggest five-year swings in Work In Process: increased 15.35% in 2023 and later rose 8.16% in 2024.
  • Year by year, Work In Process stood at $1.4 million in 2022, then grew by 15.35% to $1.6 million in 2023, then increased by 8.16% to $1.7 million in 2024, then increased by 9.45% to $1.9 million in 2025.
  • Business Quant data shows Work In Process for ZJYL at $1.9 million in Q3 2025, $1.7 million in Q3 2024, and $1.6 million in Q3 2023.